(ABUS) Arbutus Biopharma - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: CA03879J1003
ABUS: RNAi Therapeutic, Oral PD-L1 Inhibitor, Small Molecule Antiviral
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a biopharmaceutical company specializing in the development of innovative therapeutics for chronic Hepatitis B virus (HBV) infection. The companys lead product candidate, imdusiran (AB-729), is a subcutaneously administered RNA interference (RNAi) therapeutic designed to suppress all HBV antigens, including HBsAg, which plays a critical role in the viruss replication and persistence. This approach aims to address the limitations of current HBV treatments, which often fail to achieve a functional cure. Arbutus is also advancing AB-101, an oral PD-L1 inhibitor intended to reawaken the immune systems response to HBV, a strategy that complements its antiviral efforts. Additionally, the company is exploring small molecule antiviral compounds to target coronaviruses, including COVID-19, leveraging its expertise in viral diseases.
The company has established a robust network of partnerships to enhance its research and development capabilities. These include licensing agreements with prominent biopharma companies such as Gritstone Oncology, Alnylam Pharmaceuticals, Qilu Pharmaceuticals, Assembly Biosciences, Acuitas Therapeutics, and Antios Therapeutics. Furthermore, Arbutus has entered into a clinical collaboration with Barinthus Biotherapeutics to evaluate VTP-300, expanding its pipeline beyond its core HBV focus. Originally founded as Tekmira Pharmaceuticals Corporation, the company rebranded as Arbutus Biopharma Corporation in July 2015 to reflect its strategic shift toward HBV and other viral diseases. Headquartered in Warminster, Pennsylvania, Arbutus is positioned as a key player in the HBV therapeutic landscape, with a strong emphasis on innovative, curative treatments.
Over the next three months, Arbutus Biopharmas stock (NASDAQ:ABUS) is expected to experience volatility influenced by both technical and fundamental factors. Technically, the stock is trading near its SMA 20 and SMA 50 levels of 3.37 and 3.33, respectively, with an SMA 200 of 3.57, indicating a potential near-term range-bound movement. The Average True Range (ATR) of 0.14 suggests moderate price fluctuations. From a fundamental perspective, the companys high P/S ratio of 93.87 reflects its developmental stage and market expectations for its pipeline. The negative P/E ratio underscores the companys current focus on R&D over profitability. With a market cap of $632.90M, Arbutus is well-capitalized to advance its clinical programs, but investors will closely monitor updates on imdusirans clinical progress and the broader HBV treatment landscape for cues on the stocks direction.
Additional Sources for ABUS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ABUS Stock Overview
Market Cap in USD | 639m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2015-08-03 |
ABUS Stock Ratings
Growth 5y | 39.6% |
Fundamental | -56.3% |
Dividend | 0.0% |
Rel. Strength Industry | 36.9 |
Analysts | 4.2/5 |
Fair Price Momentum | 3.13 USD |
Fair Price DCF | - |
ABUS Dividends
No Dividends PaidABUS Growth Ratios
Growth Correlation 3m | 11.3% |
Growth Correlation 12m | 38.6% |
Growth Correlation 5y | 4% |
CAGR 5y | 18.34% |
CAGR/Max DD 5y | 0.25 |
Sharpe Ratio 12m | -0.09 |
Alpha | 24.20 |
Beta | -0.30 |
Volatility | 41.82% |
Current Volume | 707.4k |
Average Volume 20d | 1016.7k |
As of March 16, 2025, the stock is trading at USD 3.30 with a total of 707,417 shares traded.
Over the past week, the price has changed by -0.30%, over one month by +0.30%, over three months by -7.04% and over the past year by +26.44%.
No, based on ValueRay Fundamental Analyses, Arbutus Biopharma (NASDAQ:ABUS) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -56.29 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABUS as of March 2025 is 3.13. This means that ABUS is currently overvalued and has a potential downside of -5.15%.
Arbutus Biopharma has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy ABUS.
- Strong Buy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ABUS Arbutus Biopharma will be worth about 3.4 in March 2026. The stock is currently trading at 3.30. This means that the stock has a potential upside of +2.42%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 5.2 | 57.6% |
Analysts Target Price | 5.1 | 53.9% |
ValueRay Target Price | 3.4 | 2.4% |